MMPU Group Molecular Pediatric Oncology (MPO)

MMPU Group Molecular Pediatric Oncology Data Access Committee
mpo-dac@mmpu.de

Request Access

Dataset ID	Description	Technology	Samples
EGAD00001004459	Each dataset cosist of WES data from 5 samples (1 patient): original leukemia initial diagnosis T-ALL, original leukemia relapse T-ALL, PDX derived of initial diagnosis T-ALL, PDX derived of relapse T-ALL, remission (normal control)	Illumina HiSeq 2000 Illumina HiSeq 2500 NextSeq 500	164
EGAD50000000831	In this study, we conducted single cell full length total RNA sequencing (VASA-seq) on 13 matched pediatric T-ALL PDX samples at initial diagnosis and relapse, along with 5 non-relapsing PDX samples collected at initial diagnosis. We identified a subpopulation of T-ALL cells with stem-like cell features that expands substantially at relapse indicating resistance to first-line therapy. Chemotherapy resistance was further validated through functional testing: Two samples were subjected to in-vitro drug testing, treated with Cytarabine for three days, followed by single-cell transcriptomic analysis using 10x Genomics. Additionally, in-vivo drug testing was conducted on one sample, involving re-engraftment into mice and treatment with a combination of Vincristine, Doxorubicin, and Dexamethasone. Single-cell transcriptomic analysis using 10x Genomics was performed after 0, 15 and 30 days of treatment.	Illumina NovaSeq 6000 NextSeq 550	69